Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure have?
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure has 5,122 citations in the OpenAlex counts ScholarIQ stores.
When was Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure published?
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure has 2020 year in the ScholarIQ index.
What is the open-access status of Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure?
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure has bronze oa status in the ScholarIQ index.
What is the DOI of Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure?
The DOI for Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure is on the source record.
What is the PMID of Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure?
The PMID for Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure is on the source record.
What is the OpenAlex record for Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure?
The OpenAlex for Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure is on the source record.